News coverage about Nevro Corp (NYSE:NVRO) has trended somewhat negative recently, according to AlphaOne Sentiment. The research firm, a service of Accern, scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nevro Corp earned a daily sentiment score of -0.11 on AlphaOne’s scale. AlphaOne also assigned news stories about the medical equipment provider an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.

Nevro Corp (NYSE:NVRO) traded down 2.83% on Friday, reaching $85.22. 640,345 shares of the company’s stock were exchanged. The firm’s market cap is $2.49 billion. Nevro Corp has a 12 month low of $61.52 and a 12 month high of $106.93. The firm’s 50-day moving average is $91.81 and its 200-day moving average is $88.25.

Nevro Corp (NYSE:NVRO) last issued its quarterly earnings data on Thursday, February 23rd. The medical equipment provider reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.14. Nevro Corp had a negative return on equity of 14.57% and a negative net margin of 18.91%. The business earned $70.50 million during the quarter, compared to analyst estimates of $66.41 million. During the same quarter last year, the firm earned ($0.51) EPS. Nevro Corp’s revenue for the quarter was up 113.0% compared to the same quarter last year. On average, equities analysts forecast that Nevro Corp will post ($0.54) earnings per share for the current year.

Several research firms have recently commented on NVRO. B. Riley restated a “buy” rating and set a $108.00 price target on shares of Nevro Corp in a report on Wednesday, March 1st. Leerink Swann boosted their price target on shares of Nevro Corp from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, February 24th. Canaccord Genuity began coverage on shares of Nevro Corp in a report on Thursday, March 23rd. They set a “buy” rating and a $120.00 price target on the stock. Northland Securities restated a “positive” rating and set a $110.00 price target on shares of Nevro Corp in a report on Thursday, February 2nd. Finally, Zacks Investment Research cut shares of Nevro Corp from a “buy” rating to a “hold” rating in a report on Wednesday, January 4th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Nevro Corp presently has a consensus rating of “Buy” and an average target price of $103.18.

ILLEGAL ACTIVITY WARNING: “Nevro Corp (NVRO) Receiving Somewhat Negative Press Coverage, Analysis Shows” was originally posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at http://www.financial-market-news.com/nevro-corp-nvro-receiving-somewhat-negative-press-coverage-analysis-shows/1406159/.

In other news, CFO Andrew H. Galligan sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $94.46, for a total value of $2,833,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael Enxing sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $93.53, for a total transaction of $140,295.00. The disclosure for this sale can be found here. Insiders sold a total of 136,180 shares of company stock valued at $12,730,657 in the last quarter. Corporate insiders own 12.10% of the company’s stock.

Nevro Corp Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.